1215358-58-9
1215358-58-9
Chemical Structure
Bilastine-d6
- CAS No.: 1215358-58-9
- Formula:C28H31D6N3O3
- Molecular Weight:469.65
IUPAC Name: 2-(3-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)-2-(methyl-d3)propanoic-3,3,3-d3 acid
InChIKey: YQBLDZMARIUXJI-XERRXZQWSA-N
SMILES: CCOCCN1C(C2CCN(CC2)CCC3=CC(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C(O)=O)=CC=C3)=NC4=CC=CC=C41
Biological Activity: Bilastine-d6 is the deuterium labeled Bilastine. Bilastine is a selective histamine H1 receptor antagonist used for treatment of allergic rhinoconjunctivitis and urticaria[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bilastine-d6 | 97.12% | Bilastine-d6 is the deuterium labeled Bilastine. Bilastine is a selective histamine H1 receptor antagonist used for treatment of allergic rhinoconjunctivitis and urticaria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bilastine (Standard) | ≥98% | Bilastine (Standard) is the analytical standard of Bilastine. This product is intended for research and analytical applications. Bilastine is a histamine H1 receptor antagonist that can be used to treat allergic rhinoconjunctivitis and urticaria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bilastine-d4 | Bilastine-d4 is deuterium labeled Bilastine. Bilastine is an oral histamine H1-receptor antagonist. Bilastine can be used for allergic rhinitis and urticaria studies, and it also improves diabetic nephropathy in mice, showing safety for the central nervous system. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bilastine | 99.83% | Bilastine is an oral histamine H1-receptor antagonist. Bilastine can be used for allergic rhinitis and urticaria studies, and it also improves diabetic nephropathy in mice, showing safety for the central nervous system. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Corcostegui, R., et al., Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D, 2005. 6(6): p. 371-84.;Jauregizar, N., et al., Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet, 2009. 48(8): p. 543-54. [Content Brief]
